I haven't had a chance to think through this more carefully, but has this CMO move minimised any litigation risks associated with the Exelogen lawsuit (vs University of Birmingham)?
Tom mentions the following in his response: "In my view, an orphan designation offers superior, legislative protection than a patent ever will (which can be potentially litigated and objected as to its validity". I understand that he is not referring to the Exelogen situation, but rather, patent infringements etc.
Thoughts?
I haven't had a chance to think through this more carefully, but...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
